Starting 1 May 2026, the EU REACH Regulation will impose new restrictions on four fluorinated surfactants (PFAS substances), impacting certain medical disinfectant wipes, disposable surgical gowns with functional coatings, and ultrasound coupling gel formulations. Companies manufacturing or importing these products into the EU — particularly those holding CE marking but containing newly restricted substances — must complete reformulation and resubmission of compliance documentation by 1 November 2026. This development is especially relevant for medical device suppliers, contract manufacturers, and specialty chemical distributors serving regulated healthcare markets.

Event Overview

Effective 1 May 2026, the EU REACH Annex XVII restriction list includes four per- and polyfluoroalkyl substances (PFAS) used as surface-active agents. The restriction applies to their use in consumer and professional medical products, specifically: disinfectant wet wipes, protective apparel (e.g., single-use surgical gowns with liquid-repellent coatings), and ultrasound coupling agents. Products already placed on the EU market under CE marking but containing any of the four listed PFAS must undergo formulation revision and regulatory re-evaluation before 1 November 2026.

Industries Affected by the Restriction

Medical Device Manufacturers

Manufacturers of disposable surgical gowns and drapes relying on PFAS-based coatings for fluid resistance are directly affected. These coatings may no longer comply with REACH post-2026 unless reformulated. Impact includes potential delays in CE conformity assessments, increased validation requirements for alternative coating systems, and possible redesign of barrier performance testing protocols.

Disinfectant Formulators and Brand Owners

Companies developing or marketing ready-to-use disinfectant wipes — especially those using PFAS for enhanced wetting, soil removal, or film-forming properties — face reformulation pressure. Affected products include both hospital-grade and professional-use disinfectants sold under CE-marked medical device classifications (Class I or Class IIa). Reformulation timelines intersect with existing biocidal product regulation (BPR) dossiers, requiring coordinated updates.

Ultrasound Coupling Gel Producers

Suppliers of sterile or non-sterile ultrasound coupling gels that incorporate PFAS as viscosity modifiers or skin-adhesion enhancers must verify ingredient composition against the restricted list. As many such gels fall under CE marking as Class I medical devices, changes trigger re-evaluation of biocompatibility, stability, and packaging compatibility — not just chemical compliance.

Contract Development and Manufacturing Organizations (CDMOs)

CDMOs supporting medical device or diagnostic accessory clients are impacted through revised technical agreements and quality agreements. They must update material specifications, supplier declarations of conformity (DoC), and change control documentation to exclude the four PFAS. Failure to align internal controls with the new REACH timeline may delay client product launches or renewals.

Key Actions for Affected Enterprises and Professionals

Verify current formulations against the four listed PFAS substances

Identify whether any of the restricted substances — by CAS number or chemical name — appear in raw material safety data sheets (SDS), supplier declarations, or internal bill-of-materials records. Prioritize review for ingredients used in surface treatment, wetting, or film formation functions.

Assess CE certification status and renewal timelines

Determine whether affected products are certified under MDR 2017/745 and whether their current Notified Body certificates expire before or after 1 November 2026. Products due for renewal in Q4 2026 or later require updated technical documentation reflecting PFAS-free formulations prior to submission.

Engage with raw material suppliers now

Contact key chemical suppliers to confirm availability of REACH-compliant alternatives, lead times for qualification batches, and supporting regulatory documentation (e.g., updated SDS, substance identity statements). Document all communications as part of change management records.

Monitor official ECHA guidance and national enforcement interpretations

While the restriction enters force on 1 May 2026, transitional provisions and enforcement priorities may vary across EU Member States. Track updates from the European Chemicals Agency (ECHA) and national competent authorities — particularly regarding definitions of 'placing on the market' and exemptions for legacy stock.

Editorial Perspective / Industry Observation

This REACH update is best understood not as an isolated regulatory amendment, but as a signal of accelerating PFAS regulation across EU health and environmental policy frameworks. Analysis shows it aligns closely with the broader EU strategy for PFAS restriction under the Chemicals Strategy for Sustainability, and precedes anticipated EU-wide bans on non-essential PFAS uses expected in 2027–2028. Observably, this restriction targets specific functional chemistries rather than entire product categories — suggesting regulators are prioritizing risk-based phase-outs over blanket prohibitions. From an industry perspective, the six-month window between entry-into-force (May 2026) and compliance deadline (November 2026) reflects increasing administrative expectations for rapid supply chain adaptation. Current more appropriate interpretation is that this is a targeted, enforceable milestone — not merely a warning — and signals growing regulatory scrutiny of functional additives in low-risk medical devices.

The restriction underscores a structural shift: compliance is increasingly defined at the molecular level, not just the product level. For companies active in EU-regulated medical markets, this reinforces the need for granular substance-level traceability across formulations and supply chains — extending beyond CE marking obligations into upstream chemical procurement governance.

Information Sources

Main source: European Chemicals Agency (ECHA) – Annex XVII to REACH Regulation, Entry updated 2026/05/01 (Official Journal of the European Union, L series, 2025 edition, published December 2025).
Additional context: EU Commission Communication on the Chemicals Strategy for Sustainability (2020), and ECHA’s 2024–2025 Work Programme.
Note: Enforcement approaches across EU Member States remain subject to national implementation and are currently under observation.